ProCE Banner Activity

CodeBreaK 200 Phase III Trial: Sotorasib vs Docetaxel for Patients With Previously Treated Advanced NSCLC With KRAS G12C Mutation

Slideset Download
Conference Coverage
In CodeBreaK 200, sotorasib significantly increased progression-free survival and ORR vs docetaxel in patients with previously treated KRAS G12C–mutated advanced non-small-cell lung cancer.

Released: September 22, 2022

Expiration: September 21, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.